Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 3/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1600945 | 0.99 | CFTR (0.39) | CFTRPTGDR2KMT2ARXFP1ALDH1A1 | |
| SCHEMBL3954842 | 0.77 | CYP2D6 (0.36) | CFTRPTGDR2TACR1GAA | |
| SCHEMBL1601403 | 0.76 | PDE2A (0.46) | CFTRPTGDR2KMT2ATACR1 | |
| SCHEMBL1600937 | 0.76 | PDE2A (0.46) | CFTRPTGDR2KMT2ATACR1 | |
| SCHEMBL4609055 | 0.75 | BACE1 (0.45) | ALDH1A1TSHR | |
| SCHEMBL1600845 | 0.75 | PDE2A (0.47) | CFTRPTGDR2TACR1 | |
| SCHEMBL1600353 | 0.75 | CYP1A2 (0.34) | CFTRPTGDR2TACR1 | |
| SCHEMBL1600354 | 0.73 | PDE2A (0.33) | CFTRPTGDR2TACR1 | |
| SCHEMBL1600352 | 0.73 | PDE2A (0.33) | CFTRPTGDR2TACR1 | |
| SCHEMBL1600421 | 0.72 | MEN1 (0.40) | CFTRKMT2ATACR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919506-B2 | Dibenzyl amine compounds and derivatives | PFIZER INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919506-B2 | Dibenzyl amine compounds and derivatives | PFIZER INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-1996564-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | Pfizer Products Incorporated (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007105050-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | PFIZER INC | 2007-09-13 | — | — | US | disclosed |
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | PFIZER INC | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | APOB, LDLR, CETP | CFTR 4149/4885PTGDR2 1421/4885KMT2A 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.